Drug sales post healthy gains for 2006, but primary care categories slip

Share this article:
Global pharmaceutical sales grew 7% to $643 billion in 2006, according to IMS Health, while US drug sales were up 8.3% to $290.1 billion for the year, thanks to Medicare Part D and strong sales of specialty products -- particularly oncologics and autoimmune agents. Specialist-driven products contributed 62% of growth, compared with just 35% in 2000, the company said. Sales of oncologics were up 20.5% to $34.6 billion, with more than 380 compounds in development, including many targeted therapies in Phase III clinical trials. Autoimmune agents like Remicade and Humira were up 20% to $10.6 billion in sales, with a boost from new indications approved for existing medications. Respiratory drug sales were up 10% to $24.6 billion, and sales of lipid drugs continued to grow, up 7.5% to $35.2 billion. But some long-reliable primary-care cash cows slipped due to generic incursions and OTC switches, with PPIs, antihistamines, platelet aggregation inhibitors and antidepressants losing ground. And products worth $14 billion in US sales lost patent protection over the course of the year.
Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union